JP2015506926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506926A5 JP2015506926A5 JP2014548277A JP2014548277A JP2015506926A5 JP 2015506926 A5 JP2015506926 A5 JP 2015506926A5 JP 2014548277 A JP2014548277 A JP 2014548277A JP 2014548277 A JP2014548277 A JP 2014548277A JP 2015506926 A5 JP2015506926 A5 JP 2015506926A5
- Authority
- JP
- Japan
- Prior art keywords
- process according
- salt
- concentration
- column
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579609P | 2011-12-22 | 2011-12-22 | |
| US61/579,609 | 2011-12-22 | ||
| US201261644831P | 2012-05-09 | 2012-05-09 | |
| US61/644,831 | 2012-05-09 | ||
| PCT/IB2012/057227 WO2013093720A2 (en) | 2011-12-22 | 2012-12-12 | Anti-diabetic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506926A JP2015506926A (ja) | 2015-03-05 |
| JP2015506926A5 true JP2015506926A5 (enExample) | 2016-02-04 |
| JP6165168B2 JP6165168B2 (ja) | 2017-07-19 |
Family
ID=47561699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548277A Expired - Fee Related JP6165168B2 (ja) | 2011-12-22 | 2012-12-12 | 抗糖尿病化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9163227B2 (enExample) |
| EP (1) | EP2793928B1 (enExample) |
| JP (1) | JP6165168B2 (enExample) |
| KR (1) | KR101640697B1 (enExample) |
| CN (1) | CN104066438B (enExample) |
| AU (1) | AU2012356219B2 (enExample) |
| BR (1) | BR112014014898A2 (enExample) |
| CA (1) | CA2859969A1 (enExample) |
| DK (1) | DK2793928T3 (enExample) |
| ES (1) | ES2623786T3 (enExample) |
| IL (1) | IL233206A (enExample) |
| MX (1) | MX2014007626A (enExample) |
| SG (1) | SG11201402640SA (enExample) |
| TW (1) | TWI560202B (enExample) |
| WO (1) | WO2013093720A2 (enExample) |
| ZA (1) | ZA201403755B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013172967A1 (en) | 2012-05-17 | 2013-11-21 | Extend Biosciences, Inc | Carriers for improved drug delivery |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| US11867696B2 (en) * | 2015-02-06 | 2024-01-09 | Cell Idx, Inc. | Antigen-coupled immunoreagents |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| BR112020000115A2 (pt) * | 2017-07-05 | 2020-07-07 | Biocells (Beijing) Biotech Co., Ltd. | sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos |
| EP3728327A1 (en) | 2017-12-22 | 2020-10-28 | F. Hoffmann-La Roche AG | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography |
| US12226451B2 (en) * | 2018-07-03 | 2025-02-18 | Bristol-Myers Squibb Company | FGF-21 formulations |
| CN115322794B (zh) | 2020-01-11 | 2025-09-19 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
| AR124395A1 (es) * | 2020-12-17 | 2023-03-22 | Intarcia Therapeutics Inc | Agonistas del receptor del polipéptido tipo glucagón 1 (glp-1) de acción prolongada y métodos de uso de los mismos |
| CN112986575B (zh) * | 2020-12-29 | 2023-03-17 | 上海药明康德新药开发有限公司 | 一种串联式验证dna编码苗头化合物修饰抗体的方法 |
| TWI837615B (zh) * | 2021-03-23 | 2024-04-01 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
| AU2022267568A1 (en) * | 2021-04-30 | 2023-11-16 | Innovent Biologics (Suzhou) Co., Ltd. | Oxm3 storage agent, oxm3 preparation, and preparation method |
| US12233115B2 (en) | 2022-09-30 | 2025-02-25 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
| WO2024238912A1 (en) * | 2023-05-17 | 2024-11-21 | OncoC4, Inc. | Ph-sensitive anti-ctla-4 antibodies and uses thereof |
| CN116804630B (zh) * | 2023-08-03 | 2024-03-05 | 中拓生物有限公司 | 一种血清同型半胱氨酸测定试剂盒 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6326176B1 (en) | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| CA2385888A1 (en) | 1999-09-27 | 2001-04-05 | The Regents Of The University Of California | Engineering antibodies that bind irreversibly |
| US6294374B1 (en) | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
| EP2163626A1 (en) | 1999-11-18 | 2010-03-17 | Novartis Vaccines and Diagnostics, Inc. | Human FGF-21 gene and gene expression products |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| AU2003201810A1 (en) | 2002-01-15 | 2003-07-30 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
| AU2004303783A1 (en) | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| EP1727559A1 (en) | 2004-01-26 | 2006-12-06 | Eli Lilly And Company | Use of fgf-21 and a thiazolidinedione for treating type 2 diabetes |
| JP2007531715A (ja) | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合ｆｇｆ−２１化合物 |
| DK1751184T3 (da) | 2004-05-13 | 2009-11-23 | Lilly Co Eli | FGF-21 fusionsproteiner |
| WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| MX2007002616A (es) | 2004-09-02 | 2007-05-16 | Lilly Co Eli | Muteinas de factor de crecimiento de fibroblasto 21. |
| EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| US20080261875A1 (en) | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
| CN101287485A (zh) * | 2005-03-03 | 2008-10-15 | 爱尔兰考夫克斯科技有限公司 | 抗血管生成化合物 |
| US20080152660A1 (en) | 2005-03-03 | 2008-06-26 | Bradshaw Curt W | Anti-Angiogenic Compounds |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| PL2068909T3 (pl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modyfikowane polipeptydy fgf-21 i ich zastosowanie |
| JP2010535781A (ja) * | 2007-08-03 | 2010-11-25 | イーライ リリー アンド カンパニー | 肥満に対する処置 |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
-
2012
- 2012-12-12 CA CA2859969A patent/CA2859969A1/en not_active Abandoned
- 2012-12-12 BR BR112014014898-8A patent/BR112014014898A2/pt not_active IP Right Cessation
- 2012-12-12 EP EP12816137.9A patent/EP2793928B1/en not_active Not-in-force
- 2012-12-12 AU AU2012356219A patent/AU2012356219B2/en not_active Ceased
- 2012-12-12 TW TW101147080A patent/TWI560202B/zh not_active IP Right Cessation
- 2012-12-12 US US13/712,873 patent/US9163227B2/en not_active Expired - Fee Related
- 2012-12-12 WO PCT/IB2012/057227 patent/WO2013093720A2/en not_active Ceased
- 2012-12-12 CN CN201280063933.4A patent/CN104066438B/zh not_active Expired - Fee Related
- 2012-12-12 MX MX2014007626A patent/MX2014007626A/es unknown
- 2012-12-12 ES ES12816137.9T patent/ES2623786T3/es active Active
- 2012-12-12 DK DK12816137.9T patent/DK2793928T3/en active
- 2012-12-12 KR KR1020147020397A patent/KR101640697B1/ko not_active Expired - Fee Related
- 2012-12-12 SG SG11201402640SA patent/SG11201402640SA/en unknown
- 2012-12-12 JP JP2014548277A patent/JP6165168B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-22 ZA ZA2014/03755A patent/ZA201403755B/en unknown
- 2014-06-17 IL IL233206A patent/IL233206A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506926A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| Dall’Acqua et al. | Antibody humanization by framework shuffling | |
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| JP6092892B2 (ja) | 抗体の精製方法 | |
| RU2019102008A (ru) | Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа | |
| JP2016196468A5 (enExample) | ||
| FI3309176T3 (fi) | Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö | |
| JP2019527047A5 (enExample) | ||
| JP2019500862A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2010227116A5 (enExample) | ||
| JP2015525211A5 (enExample) | ||
| JP2017114866A5 (enExample) | ||
| DE602005027737D1 (de) | Verfahren zur antikörpererzeugung | |
| RU2019100481A (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| HRP20191983T1 (hr) | Konstrukti protutijela za cdh19 i cd3 | |
| JP2009533021A5 (enExample) | ||
| JP2014158485A5 (enExample) | ||
| JP2014516540A5 (enExample) | ||
| TW201249999A (en) | An integrated approach to the isolation and purification of antibodies | |
| JP2008520186A5 (enExample) | ||
| JP2016519052A5 (enExample) | ||
| JP2017532005A5 (enExample) | ||
| JP2017536846A5 (enExample) |